Perfil
Elizabeth Nguyen worked as a Director-Human Resources Business Partner at InterMune, Inc. and as the Head-Human Resources Business Partnering at MyoKardia, Inc. She then served as the Senior Vice President, Head-Talent & Culture at Surrozen, Inc. Ms. Nguyen holds a graduate degree from Marymount University and an undergraduate degree from Virginia Polytechnic Institute & State University.
Antiguos cargos conocidos de Elizabeth Nguyen.
| Empresas | Cargo | Fin |
|---|---|---|
| SURROZEN, INC. | Human Resources Officer | 01/07/2023 |
| INTERMUNE INC | Human Resources Officer | - |
| MYOKARDIA, INC. | Human Resources Officer | - |
Formación de Elizabeth Nguyen.
| Marymount University | Graduate Degree |
| Virginia Polytechnic Institute & State University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| SURROZEN, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Elizabeth Nguyen
